Retina

Leo A. Kim, MD, PhD, Next Incumbent of the Monte J. Wallace Ophthalmology Chair in Retina at Mass Eye and Ear

March 1, 2022

Dr. Leo KimLeo A. Kim, MD, PhD, a clinician scientist with surgical expertise and an innovator in the treatment of retinal diseases associated with neovascularization and fibrosis and an Associate Professor of Ophthalmology at Harvard Medical School, will serve as the next incumbent of the Monte J. Wallace Ophthalmology Chair in Retina at Mass Eye and Ear, effective December 1, 2021.... Read more about Leo A. Kim, MD, PhD, Next Incumbent of the Monte J. Wallace Ophthalmology Chair in Retina at Mass Eye and Ear

Researchers Identify Metabolomics as a Potential Tool to Improve Diagnostic and Prognostic Information on AMD

July 9, 2019

A recent meta-analysis, led by Deeba Husain, MD, suggests that AMD patients present distinct plasma metabolomic profiles, which vary with disease severity. After analyzing blood samples of their 491 patients from two cohorts–one in Boston and one in Coimbra, Portugal–they found that metabolites differed significantly between AMD patients as compared to controls, and with various stages of the disease.... Read more about Researchers Identify Metabolomics as a Potential Tool to Improve Diagnostic and Prognostic Information on AMD

Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation

February 27, 2019
OCU400, a novel gene therapy platform developed by Neena Haider, PhD, Harvard Medical School Associate Professor of Ophthalmology and Associate Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and licensed to biopharmaceutical company Ocugen, Inc., has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).... Read more about Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation